Market capitalization | $8.42m |
Enterprise Value | $10.99m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | negative |
Cash position | $40.00k |
Short interest | 4.65% |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
1 Analyst has issued a forecast Nymox Pharmaceutical Corp:
1 Analyst has issued a forecast Nymox Pharmaceutical Corp:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -0.65 -0.65 |
36%
36%
|
Net Profit | -0.72 -0.72 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
Head office | Bahamas |
CEO | Paul Averback |
Founded | 1995 |
Website | www.nymox.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.